Article: Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleCapecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer
AuthorsChua, D1 2
Wei, WI1
Sham, JST1
Au, GKH1
KeywordsCapecitabine
Hand-foot syndrome
Nasopharyngeal carcinoma
Palliative chemotherapy
Issue Date2008
PublisherOxford University Press. The Journal's web site is located at http://jjco.oxfordjournals.org/
CitationJapanese Journal Of Clinical Oncology, 2008, v. 38 n. 4, p. 244-249 [How to Cite?]
DOI: http://dx.doi.org/10.1093/jjco/hyn022
Abstractbackground: Capecitabine monotherapy had activity in recurrent/metastatic nasopharyngeal carcinoma (NPC) as demonstrated previously in a small pilot study. We conducted a retrospective review of patients who received capecitabine for recurrent and metastatic NPC to further evaluate its clinical benefits. Methods: Forty-nine patients with recurrent and metastatic NPC received capecitabine at a dose of 1-1.25 G/m2 twice daily for 14 days in 3-week cycles. Disease sites were locoregional in 29%, distant in 45% and locoregional plus distant in 26%. All except one had prior platinum-based chemotherapy for relapse or as adjunctive treatment. Median follow-up was 10 months (range: 3-41). Results: Treatment was generally well tolerated. Hand-foot syndrome was common and occurred in 86%; (25% Grade 3). Grade 3 hematological toxicity occurred in 6%. Partial response rate was 31% (95% CI: 18%, 44%) and complete response rate was 6% (95% CI: 0%, 13%), for an overall response rate of 37% (95% CI: 23%, 50%). Median time-to-progression was 5 months and median survival was 14 months. One- and two-year survival rates were 54 and 26%, respectively. Significantly better survival was observed in patients treated for locoregional recurrence and those with severe hand-foot syndrome. Conclusions: Capecitabine has single agent activity in NPC and severe hand-foot syndrome predicts favorable outcome. Based on our experience, capecitabine monotherapy should be considered in patients with recurrent/ metastatic NPC. © The Author (2008). Published by Oxford University Press. All rights reserved.
ISSN0368-2811
2011 Impact Factor: 1.783
2011 SCImago Journal Rankings: 0.164
DOIhttp://dx.doi.org/10.1093/jjco/hyn022
ISI Accession Number IDWOS:000255439200002
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorChua, D
dc.contributor.authorWei, WI
dc.contributor.authorSham, JST
dc.contributor.authorAu, GKH
dc.date.accessioned2010-09-06T08:41:39Z
dc.date.available2010-09-06T08:41:39Z
dc.date.issued2008
dc.description.abstractbackground: Capecitabine monotherapy had activity in recurrent/metastatic nasopharyngeal carcinoma (NPC) as demonstrated previously in a small pilot study. We conducted a retrospective review of patients who received capecitabine for recurrent and metastatic NPC to further evaluate its clinical benefits. Methods: Forty-nine patients with recurrent and metastatic NPC received capecitabine at a dose of 1-1.25 G/m2 twice daily for 14 days in 3-week cycles. Disease sites were locoregional in 29%, distant in 45% and locoregional plus distant in 26%. All except one had prior platinum-based chemotherapy for relapse or as adjunctive treatment. Median follow-up was 10 months (range: 3-41). Results: Treatment was generally well tolerated. Hand-foot syndrome was common and occurred in 86%; (25% Grade 3). Grade 3 hematological toxicity occurred in 6%. Partial response rate was 31% (95% CI: 18%, 44%) and complete response rate was 6% (95% CI: 0%, 13%), for an overall response rate of 37% (95% CI: 23%, 50%). Median time-to-progression was 5 months and median survival was 14 months. One- and two-year survival rates were 54 and 26%, respectively. Significantly better survival was observed in patients treated for locoregional recurrence and those with severe hand-foot syndrome. Conclusions: Capecitabine has single agent activity in NPC and severe hand-foot syndrome predicts favorable outcome. Based on our experience, capecitabine monotherapy should be considered in patients with recurrent/ metastatic NPC. © The Author (2008). Published by Oxford University Press. All rights reserved.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationJapanese Journal Of Clinical Oncology, 2008, v. 38 n. 4, p. 244-249 [How to Cite?]
DOI: http://dx.doi.org/10.1093/jjco/hyn022
dc.identifier.doihttp://dx.doi.org/10.1093/jjco/hyn022
dc.identifier.epage249
dc.identifier.hkuros141513
dc.identifier.isiWOS:000255439200002
dc.identifier.issn0368-2811
2011 Impact Factor: 1.783
2011 SCImago Journal Rankings: 0.164
dc.identifier.issue4
dc.identifier.openurl
dc.identifier.pmid18407933
dc.identifier.scopuseid_2-s2.0-42549151234
dc.identifier.spage244
dc.identifier.urihttp://hdl.handle.net/10722/83489
dc.identifier.volume38
dc.languageeng
dc.publisherOxford University Press. The Journal's web site is located at http://jjco.oxfordjournals.org/
dc.publisher.placeUnited Kingdom
dc.relation.ispartofJapanese Journal of Clinical Oncology
dc.relation.referencesReferences in Scopus
dc.rightsJapanese Journal of Clinical Oncology. Copyright © Oxford University Press.
dc.subjectCapecitabine
dc.subjectHand-foot syndrome
dc.subjectNasopharyngeal carcinoma
dc.subjectPalliative chemotherapy
dc.titleCapecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. Queen Mary Hospital Hong Kong